156 related articles for article (PubMed ID: 37291888)
21. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
Offin M; Shaverdian N; Rimner A; Lobaugh S; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Lee N; Kris MG; Rudin CM; Zhang Z; Hellmann MD; Chaft JE; Gomez DR
Radiother Oncol; 2020 Aug; 149():205-211. PubMed ID: 32361014
[TBL] [Abstract][Full Text] [Related]
22. Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer.
Sankar K; Bryant AK; Strohbehn GW; Zhao L; Elliott D; Moghanaki D; Kelley MJ; Ramnath N; Green MD
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158881
[TBL] [Abstract][Full Text] [Related]
23. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
Wang Y; Zhang T; Huang Y; Li W; Zhao J; Yang Y; Li C; Wang L; Bi N
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1154-1164. PubMed ID: 34963558
[TBL] [Abstract][Full Text] [Related]
24. Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer.
Verma V; Moreno AC; Haque W; Fang P; Lin SH
J Natl Compr Canc Netw; 2018 May; 16(5):508-516. PubMed ID: 29752325
[No Abstract] [Full Text] [Related]
25. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
[TBL] [Abstract][Full Text] [Related]
26. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.
Kishi N; Matsuo Y; Shintani T; Ogura M; Mitsuyoshi T; Araki N; Fujii K; Okumura S; Nakamatsu K; Kishi T; Atsuta T; Sakamoto T; Ohtsu S; Katagiri T; Narabayashi M; Fujishiro S; Iizuka Y; Ozasa H; Hirai T; Mizowaki T;
J Radiat Res; 2023 Jan; 64(1):142-153. PubMed ID: 36149029
[TBL] [Abstract][Full Text] [Related]
27. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N; Bar J; Garrido P; Garassino MC; McDonald F; Mornex F; Filippi AR; Smit HJM; Peters S; Field JK; Christoph DC; Sibille A; Fietkau R; Haakensen VD; Chouaid C; Markman B; Hiltermann TJN; Taus A; Sawyer W; Allen A; Chander P; Licour M; Solomon B
J Thorac Oncol; 2023 Feb; 18(2):181-193. PubMed ID: 36307040
[TBL] [Abstract][Full Text] [Related]
28. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
[TBL] [Abstract][Full Text] [Related]
29. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
[TBL] [Abstract][Full Text] [Related]
30. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
[TBL] [Abstract][Full Text] [Related]
31. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
[TBL] [Abstract][Full Text] [Related]
32. Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.
Bryant AK; Sankar K; Strohbehn GW; Zhao L; Elliott D; Daniel V; Ramnath N; Green MD
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):60-65. PubMed ID: 35115216
[TBL] [Abstract][Full Text] [Related]
33. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812).
Maggiore RJ; Zahrieh D; McMurray RP; Feliciano JL; Samson P; Mohindra P; Chen H; Wong ML; Lafky JM; Jatoi A; Le-Rademacher JG
J Geriatr Oncol; 2021 May; 12(4):563-571. PubMed ID: 32950428
[TBL] [Abstract][Full Text] [Related]
34. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
35. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective.
Mehra R; Yong C; Seal B; van Keep M; Raad A; Zhang Y
J Natl Compr Canc Netw; 2021 Feb; 19(2):153-162. PubMed ID: 33545688
[TBL] [Abstract][Full Text] [Related]
37. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
38. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Spigel DR; Faivre-Finn C; Gray JE; Vicente D; Planchard D; Paz-Ares L; Vansteenkiste JF; Garassino MC; Hui R; Quantin X; Rimner A; Wu YL; Özgüroğlu M; Lee KH; Kato T; de Wit M; Kurata T; Reck M; Cho BC; Senan S; Naidoo J; Mann H; Newton M; Thiyagarajah P; Antonia SJ
J Clin Oncol; 2022 Apr; 40(12):1301-1311. PubMed ID: 35108059
[TBL] [Abstract][Full Text] [Related]
39. Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium.
Walraven I; Damhuis RA; Ten Berge MG; Rosskamp M; van Eycken L; de Ruysscher D; Belderbos JSA
Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):e177-e185. PubMed ID: 28780009
[TBL] [Abstract][Full Text] [Related]
40. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Herbst RS; Majem M; Barlesi F; Carcereny E; Chu Q; Monnet I; Sanchez-Hernandez A; Dakhil S; Camidge DR; Winzer L; Soo-Hoo Y; Cooper ZA; Kumar R; Bothos J; Aggarwal C; Martinez-Marti A
J Clin Oncol; 2022 Oct; 40(29):3383-3393. PubMed ID: 35452273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]